Biocomposites announces expanded approval for STIMULAN® Rapid Cure to be mixed with antimicrobials to treat infection
STIMULAN® Rapid Cure can now be used with both a wider range of antibiotics and also with antifungals in India
STIMULAN® Rapid Cure can be placed in bone and surrounding soft tissue to assist in wound healing and treatment of infection
Keele, UK, 25 November 2025 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces it has gained an expanded approval in India for STIMULAN® Rapid Cure. The approval from India’s Central Drugs Standard Control Organisation (CDSCO) allows STIMULAN® Rapid Cure to be mixed with a wider variety of antibiotics than before, including in combination, and also with antifungals, to assist in wound healing and treatment of infection.
